QRG Capital Management Inc. Has $5.31 Million Stock Position in IQVIA Holdings Inc. $IQV

QRG Capital Management Inc. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 592.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,124 shares of the medical research company’s stock after acquiring an additional 26,630 shares during the quarter. QRG Capital Management Inc.’s holdings in IQVIA were worth $5,308,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. WINTON GROUP Ltd bought a new stake in shares of IQVIA during the third quarter worth $3,383,000. J. Safra Sarasin Holding AG lifted its stake in shares of IQVIA by 174.3% in the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock valued at $2,891,000 after acquiring an additional 8,151 shares during the last quarter. CWM LLC boosted its holdings in shares of IQVIA by 23.9% during the 4th quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after acquiring an additional 10,762 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new stake in IQVIA during the 4th quarter worth $15,724,000. Finally, Calamos Advisors LLC increased its holdings in IQVIA by 268.1% in the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 0.3%

NYSE IQV opened at $206.38 on Monday. The firm has a market capitalization of $34.44 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 1.78 and a beta of 1.20. The business’s 50-day moving average price is $176.95 and its two-hundred day moving average price is $189.05. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts have recently commented on IQV shares. HSBC set a $210.00 price target on IQVIA in a research note on Wednesday, June 3rd. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Morgan Stanley reissued an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $222.00.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.